{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lipid+A%2C+Monophosphoryl",
    "query": {
      "intervention": "Lipid A, Monophosphoryl"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lipid+A%2C+Monophosphoryl&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T02:24:01.377Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02557633",
      "title": "A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Grass MATA MPL 10200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL 18200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 2,
      "location_summary": "Neptune City, New Jersey • Newark, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557633"
    },
    {
      "nct_id": "NCT01556945",
      "title": "Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria, Falciparum"
      ],
      "interventions": [
        {
          "name": "FMP1/AS02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RTS,S/AS02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS02 adjuvant alone",
          "type": "OTHER"
        },
        {
          "name": "Malaria challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 72,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556945"
    },
    {
      "nct_id": "NCT00057330",
      "title": "HerpeVac Trial for Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8323,
      "start_date": "2003-01-14",
      "completion_date": "2009-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057330"
    },
    {
      "nct_id": "NCT01717950",
      "title": "Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "Na-APR-1 (M74)/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gluco-Pyranosylphospho-Lipid A Aqueous Formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-09",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01717950"
    },
    {
      "nct_id": "NCT01168401",
      "title": "Bivalent Norovirus Vaccine Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "NoV GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 102,
      "start_date": "2010-09-03",
      "completion_date": "2013-01-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-23",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 3,
      "location_summary": "Silver Springs, Maryland • St Louis, Missouri • Rochester, New York",
      "locations": [
        {
          "city": "Silver Springs",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168401"
    },
    {
      "nct_id": "NCT00001042",
      "title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lipid A, Monophosphoryl",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lipid A, Liposome-encapsulated monophosphoryl",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Syntex adjuvant formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Threonyl Muramyl Dipeptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MTP-PE/MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 112,
      "start_date": null,
      "completion_date": "1996-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Rochester, New York • Seattle, Washington",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001042"
    },
    {
      "nct_id": "NCT01751048",
      "title": "LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leishmaniasis"
      ],
      "interventions": [
        {
          "name": "GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LEISH-F3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MPL-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-03",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01751048"
    },
    {
      "nct_id": "NCT06863142",
      "title": "Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Prevention",
        "Seasonal Influenza"
      ],
      "interventions": [
        {
          "name": "VRC-FLUMOS0116-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALFQ",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-04-28",
      "completion_date": "2027-02-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06863142"
    },
    {
      "nct_id": "NCT02142504",
      "title": "Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus Prevention"
      ],
      "interventions": [
        {
          "name": "Norovirus Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 454,
      "start_date": "2014-05-15",
      "completion_date": "2016-01-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 10,
      "location_summary": "San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02142504"
    },
    {
      "nct_id": "NCT03039790",
      "title": "Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Norovirus"
      ],
      "interventions": [
        {
          "name": "NoV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 528,
      "start_date": "2017-02-21",
      "completion_date": "2021-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-11-09",
      "last_synced_at": "2026-09-30T02:24:01.377Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03039790"
    }
  ]
}